Peregrine Pharmaceuticals Inc (PPHM)

4.60
0.62 11.88
NASDAQ : Health Care
Prev Close 5.22
Open 5.14
Day Low/High 4.45 / 5.26
52 Wk Low/High 0.29 / 1.32
Volume 482.11K
Avg Volume 224.00K
Exchange NASDAQ
Shares Outstanding 45.07M
Market Cap 234.36M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Peregrine Pharmaceuticals Announces Reverse Stock Split

Peregrine Pharmaceuticals Announces Reverse Stock Split

Common Stock to Trade on Split-Adjusted Basis Beginning at Opening of Market on July 10, 2017; Intended to Enable Continued Listing on the NASDAQ Capital Market

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 12%

In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.62 on the day. This compares to an average yield of 10.04% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 13%

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 13% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $20.16 on the day. This compares to an average yield of 11.31% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark

In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.80 on the day. This compares to an average yield of 9.98% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress

Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress

Ongoing Biomarker Analysis Has Identified a Biomarker that is Associated with a Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination